Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer.

2 , 32 , 33 Biomarker testing rates for metastatic prostate cancer remained low (34%) within this community oncology practice setting (although an increasing trend is observed between 2018 and 2022) despite approvals for PARP inhibitors during this period.

also in 63,971 other papers

A decreasing trend in NSCLC diagnoses was observed beginning in 2020 and continuing through 2022 ( Figure 2A ), which may reflect disruptions in cancer detection during the COVID-19 pandemic.

also in 47,180 other papers